Literature DB >> 7827202

Is the Durie and Salmon diagnostic classification system for plasma cell dyscrasias still the best choice? Application of three classification systems to a large population-based registry of paraproteinemia and multiple myeloma.

F Ong1, J Hermans, E M Noordijk, J C Kluin-Nelemans.   

Abstract

There are a number of systems for diagnosing multiple myeloma, myeloma variants and monoclonal gammopathy of undetermined significance. We compared three systems, those according to Durie and Salmon, to Kyle and Greipp, and to the British Columbia Cancer Agency, using material from a population-based registry of 847 patients with a paraproteinemia or multiple myeloma. Of these, 157 underwent both bone marrow and X-ray examinations and were subsequently included in our analysis. The differences between the systems were small, even though in only 64% of the cases the diagnosis according to all three systems was identical. The system used by the British Columbia Cancer Agency turned out to be the shortest and easiest system reviewed here. We propose a more frequent application of this system instead of the more commonly used Durie and Salmon and Kyle and Greipp criteria.

Entities:  

Mesh:

Year:  1995        PMID: 7827202     DOI: 10.1007/bf01715377

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  13 in total

Review 1.  Advances in the diagnosis and management of myeloma.

Authors:  P R Greipp
Journal:  Semin Hematol       Date:  1992-07       Impact factor: 3.851

Review 2.  Plasma cell dyscrasias: current status.

Authors:  R A Kyle; P A Greipp
Journal:  Crit Rev Oncol Hematol       Date:  1988       Impact factor: 6.312

Review 3.  Monoclonal gammopathies of undetermined significance.

Authors:  R A Kyle; J A Lust
Journal:  Semin Hematol       Date:  1989-07       Impact factor: 3.851

Review 4.  Staging and kinetics of multiple myeloma.

Authors:  B G Durie
Journal:  Semin Oncol       Date:  1986-09       Impact factor: 4.929

Review 5.  Unusual manifestations of monoclonal gammopathies. Autoimmune and idiopathic syndromes.

Authors:  D B Duggan; A Schattner
Journal:  Am J Med       Date:  1986-11       Impact factor: 4.965

Review 6.  The treatment of multiple myeloma.

Authors:  R Alexanian; M Dimopoulos
Journal:  N Engl J Med       Date:  1994-02-17       Impact factor: 91.245

Review 7.  Localized Plasmacytomas.

Authors:  R Bataille
Journal:  Clin Haematol       Date:  1982-02

8.  C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system.

Authors:  R Bataille; M Boccadoro; B Klein; B Durie; A Pileri
Journal:  Blood       Date:  1992-08-01       Impact factor: 22.113

9.  A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival.

Authors:  B G Durie; S E Salmon
Journal:  Cancer       Date:  1975-09       Impact factor: 6.860

Review 10.  Monoclonal gammopathies: new approaches to clinical problems in diagnosis and prognosis.

Authors:  P R Greipp
Journal:  Blood Rev       Date:  1989-12       Impact factor: 8.250

View more
  3 in total

1.  Presenting signs and symptoms in multiple myeloma: high percentages of stage III among patients without apparent myeloma-associated symptoms.

Authors:  F Ong; J Hermans; E M Noordijk; P W Wijermans; J C Kluin-Nelemans
Journal:  Ann Hematol       Date:  1995-03       Impact factor: 3.673

2.  Treatment with Thalidomide and Cyclophosphamide (TCID) is Superior to Vincristine (VID) and to Vinorelbine (VRID) Regimens in Patients with Refractory or Recurrent Multiple Myeloma.

Authors:  Britta Auel; Hartmut Goldschmidt; Thomas Geer; Thomas M Moehler; Uwe Platzbecker; Ralph Naumann; Igor Blau; Mathias Hänel; Wolfgang Knauf; Holger Nückel; Hans-Jürgen Salwender; Christof Scheid; Katja Weisel; Marcus Gorschlüter; Axel Glasmacher; Ingo G H Schmidt-Wolf
Journal:  Indian J Hematol Blood Transfus       Date:  2011-08-18       Impact factor: 0.900

3.  Oligosecretory multiple myeloma: a case report.

Authors:  Ujjawal Khurana; Deepti Joshi; John A Santoshi; Tanya Sharma; Neelkamal Kapoor
Journal:  Blood Res       Date:  2016-03-25
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.